Cargando…
Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer
BACKGROUND: Combination chemotherapy has contributed to increased survival from Hodgkin disease (HD) and testicular cancer (TC). However, questions concerning the quality of spermatozoa after treatment have arisen. While studies have shown evidence of DNA damage and aneuploidy in spermatozoa years f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826600/ https://www.ncbi.nlm.nih.gov/pubmed/36611168 http://dx.doi.org/10.1186/s13148-022-01417-1 |
_version_ | 1784866890633445376 |
---|---|
author | Chan, Donovan Oros Klein, Kathleen Riera-Escamilla, Antoni Krausz, Csilla O’Flaherty, Cristian Chan, Peter Robaire, Bernard Trasler, Jacquetta M. |
author_facet | Chan, Donovan Oros Klein, Kathleen Riera-Escamilla, Antoni Krausz, Csilla O’Flaherty, Cristian Chan, Peter Robaire, Bernard Trasler, Jacquetta M. |
author_sort | Chan, Donovan |
collection | PubMed |
description | BACKGROUND: Combination chemotherapy has contributed to increased survival from Hodgkin disease (HD) and testicular cancer (TC). However, questions concerning the quality of spermatozoa after treatment have arisen. While studies have shown evidence of DNA damage and aneuploidy in spermatozoa years following anticancer treatment, the sperm epigenome has received little attention. Our objectives here were to determine the impact of HD and TC, as well as their treatments, on sperm DNA methylation. Semen samples were collected from community controls (CC) and from men undergoing treatment for HD or TC, both before initiation of chemotherapy and at multiple times post-treatment. Sperm DNA methylation was assessed using genome-wide and locus-specific approaches. RESULTS: Imprinted gene methylation was not affected in the sperm of HD or TC men, before or after treatment. Prior to treatment, using Illumina HumanMethylation450 BeadChip (450 K) arrays, a subset of 500 probes was able to distinguish sperm samples from TC, HD and CC subjects; differences between groups persisted post-treatment. Comparing altered sperm methylation between HD or TC patients versus CC men, twice as many sites were affected in TC versus HD men; for both groups, the most affected CpGs were hypomethylated. For TC patients, the promoter region of GDF2 contained the largest region of differential methylation. To assess alterations in DNA methylation over time/post-chemotherapy, serial samples from individual patients were compared. With restriction landmark genome scanning and 450 K array analyses, some patients who underwent chemotherapy showed increased alterations in DNA methylation, up to 2 to 3 years post-treatment, when compared to the CC cohort. Similarly, a higher-resolution human sperm-specific assay that includes assessment of environmentally sensitive regions, or “dynamic sites,” also demonstrated persistently altered sperm DNA methylation in cancer patients post-treatment and suggested preferential susceptibility of “dynamic” CpG sites. CONCLUSIONS: Distinct sperm DNA methylation signatures were present pre-treatment in men with HD and TC and may help explain increases in birth defects reported in recent clinical studies. Epigenetic defects in spermatozoa of some cancer survivors were evident even up to 2 years post-treatment. Abnormalities in the sperm epigenome both pre- and post-chemotherapy may contribute to detrimental effects on future reproductive health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01417-1. |
format | Online Article Text |
id | pubmed-9826600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98266002023-01-09 Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer Chan, Donovan Oros Klein, Kathleen Riera-Escamilla, Antoni Krausz, Csilla O’Flaherty, Cristian Chan, Peter Robaire, Bernard Trasler, Jacquetta M. Clin Epigenetics Research BACKGROUND: Combination chemotherapy has contributed to increased survival from Hodgkin disease (HD) and testicular cancer (TC). However, questions concerning the quality of spermatozoa after treatment have arisen. While studies have shown evidence of DNA damage and aneuploidy in spermatozoa years following anticancer treatment, the sperm epigenome has received little attention. Our objectives here were to determine the impact of HD and TC, as well as their treatments, on sperm DNA methylation. Semen samples were collected from community controls (CC) and from men undergoing treatment for HD or TC, both before initiation of chemotherapy and at multiple times post-treatment. Sperm DNA methylation was assessed using genome-wide and locus-specific approaches. RESULTS: Imprinted gene methylation was not affected in the sperm of HD or TC men, before or after treatment. Prior to treatment, using Illumina HumanMethylation450 BeadChip (450 K) arrays, a subset of 500 probes was able to distinguish sperm samples from TC, HD and CC subjects; differences between groups persisted post-treatment. Comparing altered sperm methylation between HD or TC patients versus CC men, twice as many sites were affected in TC versus HD men; for both groups, the most affected CpGs were hypomethylated. For TC patients, the promoter region of GDF2 contained the largest region of differential methylation. To assess alterations in DNA methylation over time/post-chemotherapy, serial samples from individual patients were compared. With restriction landmark genome scanning and 450 K array analyses, some patients who underwent chemotherapy showed increased alterations in DNA methylation, up to 2 to 3 years post-treatment, when compared to the CC cohort. Similarly, a higher-resolution human sperm-specific assay that includes assessment of environmentally sensitive regions, or “dynamic sites,” also demonstrated persistently altered sperm DNA methylation in cancer patients post-treatment and suggested preferential susceptibility of “dynamic” CpG sites. CONCLUSIONS: Distinct sperm DNA methylation signatures were present pre-treatment in men with HD and TC and may help explain increases in birth defects reported in recent clinical studies. Epigenetic defects in spermatozoa of some cancer survivors were evident even up to 2 years post-treatment. Abnormalities in the sperm epigenome both pre- and post-chemotherapy may contribute to detrimental effects on future reproductive health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01417-1. BioMed Central 2023-01-07 /pmc/articles/PMC9826600/ /pubmed/36611168 http://dx.doi.org/10.1186/s13148-022-01417-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chan, Donovan Oros Klein, Kathleen Riera-Escamilla, Antoni Krausz, Csilla O’Flaherty, Cristian Chan, Peter Robaire, Bernard Trasler, Jacquetta M. Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title | Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title_full | Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title_fullStr | Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title_full_unstemmed | Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title_short | Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer |
title_sort | sperm dna methylome abnormalities occur both pre- and post-treatment in men with hodgkin disease and testicular cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826600/ https://www.ncbi.nlm.nih.gov/pubmed/36611168 http://dx.doi.org/10.1186/s13148-022-01417-1 |
work_keys_str_mv | AT chandonovan spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT oroskleinkathleen spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT rieraescamillaantoni spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT krauszcsilla spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT oflahertycristian spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT chanpeter spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT robairebernard spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer AT traslerjacquettam spermdnamethylomeabnormalitiesoccurbothpreandposttreatmentinmenwithhodgkindiseaseandtesticularcancer |